This trial is active, not recruiting.

Condition leukemia, lymphocytic, chronic, b-cell
Treatment bi 836826
Phase phase 1
Sponsor Boehringer Ingelheim
Start date February 2011
End date October 2016
Trial size 60 participants
Trial identifier NCT01296932, 1270.1, 2010-021488-34


Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
bi 836826
Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.

Primary Outcomes

Determination of the maximum tolerated dose of BI 836826
time frame: 12 months
Incidence of dose limiting toxicity (DLT)
time frame: 12 months

Secondary Outcomes

Number of lymphocytes in the peripheral blood
time frame: 12 months
Tumour size
time frame: 12 months
Blood counts
time frame: 12 months
Best overall response
time frame: 12 months
Progression free survival
time frame: 12 months
Failure free survival
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: 1. Diagnosis of relapsed or refractory chronic lymphocytic leukaemia. 2. At least two prior treatment regimens for chronic lymphocytic leukaemia. 3. At least one criterion for active disease as defined by the International Workshop on CLL. 4. Absolute lymphocyte count lower than 200 x 10^9/l . 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2. 6. Age 18 years or older. 7. Written informed consent which is consistent with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines and local legislation. Exclusion criteria: 1. Treatment with anti CD 20 therapy within 4 weeks, or alemtuzumab within 8 weeks, or any cytotoxic antileukemia therapy within 2 weeks, Ibrutinib or Idelalisib within 1 week prior to the first administration of the trial drug. 2. Prior allogeneic stem cell transplantation. 3. Active autoimmune haemolytic anemia. 4. Active autoimmune thrombocytopenia. 5. Known transformation to an aggressive B-cell malignancy. 6. Concurrent treatment with relevant doses of systemic glucocorticosteroids. 7. Prior history of malignancy other than chronic lymphocytic leukaemia (exceptions to this rule are defined in the clinical trial protocol). 8. Aspartate aminotransferase or alanine aminotransferase > 2.5 x upper limit of normal. 9. Total bilirubin > 1.5 x upper limit of normal. 10. Absolute Neutrophil Count < 1.000/µl. 11. Platelets < 25.000/µL. 12. Estimated Glomerular Filtration Rate <45 mL/min. 13. Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher. 14. Significant concurrent disease. 15. Any infectious disease requiring treatment at the time of enrolment or within the previous 2 weeks. 16. Hepatitis B or C. 17. Human Immunodeficiency Virus (HIV) infection. 18. Cytomegalovirus (CMV) viremia. 19. Women of childbearing potential not using a highly effective method of birth control during the trial until one year after the last dose. 20. Pregnancy or breast feeding. 21. Known or suspected active alcohol or drug abuse. 22. Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial. 23. Prior treatment with BI 836826. 24. Patients unable to comply with the protocol

Additional Information

Official title A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Boehringer Ingelheim.
Location data was received from the National Cancer Institute and was last updated in October 2016.